Castration-Resistant Prostate Cancer Treatment Principles
Definition and Diagnosis
- The American Urological Association defines castration-resistant prostate cancer as disease progression despite maintaining castrate serum testosterone levels (<50 ng/dL or <1.7 nmol/L) 1
Treatment Approach
- The European Association of Urology recommends continuing androgen deprivation therapy (ADT) with LHRH agonist or antagonist indefinitely throughout all subsequent treatments for CRPC 1
- For asymptomatic patients with non-metastatic CRPC, observation with continued ADT is the recommended approach, as no treatment has demonstrated survival benefit or clinically meaningful delay in metastasis development 2, 1
Treatment by Clinical Scenario
- For patients with good performance status who have not received docetaxel, offer abiraterone + prednisone, enzalutamide, or docetaxel as first-line options, as these treatments have demonstrated radiographic progression-free survival benefit and overall survival advantage 1, 2, 3
- For symptomatic patients with good performance status and no prior docetaxel, offer docetaxel chemotherapy as the preferred option, as it provides both survival benefit and symptom palliation 2, 3
- For patients with poor performance status, palliative care should be offered as the primary approach, with consideration of abiraterone + prednisone, enzalutamide, ketoconazole + steroid, or radionuclide therapy for select patients 4, 3
Special Populations and Molecular Considerations
- The National Comprehensive Cancer Network recommends early somatic genetic testing for all patients with mCRPC to identify actionable alterations, such as BRCA1/2 and HRR alterations 4
- For patients with BRCA1/2 positive, ARPI-naïve, PARPi + ARPI combination (talazoparib + enzalutamide or olaparib/niraparib + abiraterone) is recommended 4
Bone Health Management
- The American College of Clinical Oncology recommends that all patients with mCRPC and bony metastases receive a bone-protective agent (zoledronic acid or denosumab) to reduce skeletal-related events 5
Definition and Management of Castrate-Resistant Prostate Cancer
Introduction to CRPC
- The American Urological Association defines castrate-resistant prostate cancer as disease progression, evidenced by a rising PSA level and/or radiographic progression, that occurs despite maintaining castrate levels of serum testosterone, with a strength of evidence level of high 6, 7, 8, 9, 10
Biochemical Criteria for CRPC
- The Prostate Cancer Clinical Trials Working Group 2 established specific PSA criteria that must be met, including a PSA rise greater than 2 ng/mL above the nadir value, a rise of at least 25% over the nadir, and confirmation by a second PSA measurement at least 3 weeks later, with a moderate level of evidence 6, 8, 11, 12
Clinical Presentations of CRPC
- Non-metastatic CRPC is characterized by rising PSA with castrate testosterone, no radiographic evidence of metastatic disease, and the patient is typically asymptomatic, with a low level of evidence 11, 12
- Metastatic CRPC is documented by metastatic disease on imaging, can be asymptomatic or symptomatic, and performance status is critical for treatment selection, with a high level of evidence 6, 7, 12
Timing and Natural History
- Most patients with advanced prostate cancer progress to CRPC on average between 1-3 years after initiating castration, which is an inevitable progression and not a treatment failure, with a high level of evidence 6, 7, 9, 12, 13
Modern Therapeutic Implications
- Next-generation AR-signaling inhibitors, such as enzalutamide and abiraterone, provide a survival benefit for patients with CRPC, with a high level of evidence 9
- Chemotherapy with docetaxel and cabazitaxel improves survival in patients with CRPC, with a moderate level of evidence 6, 13
Guideline‑Recommended Radiotherapy and Systemic Therapies for Low‑Volume Castration‑Resistant Prostate Cancer
Prostate‑Directed Radiotherapy: Lack of Evidence
- No randomized clinical trials have shown any survival, progression‑free survival, or quality‑of‑life benefit from delivering radiotherapy to the primary prostate tumor in patients with castration‑resistant prostate cancer (CRPC) (Level 1 evidence) 14, 15.
Palliative Radiotherapy for Bone Metastases
- External‑beam radiotherapy is indicated for painful bone metastases; a single 8 Gy fraction provides pain relief that is equivalent to multi‑fraction schedules (Level 1 evidence) 16, 17, 18.
- Radium‑223 is recommended for symptomatic patients with bone‑only metastases and good performance status; it improves overall survival (median 14.9 mo vs 11.3 mo; hazard ratio 0.695), delays skeletal‑related events, and enhances quality of life (Level 1 evidence) 14, 19.
Radiotherapy for Metastatic Spinal Cord Compression
- High‑dose fractionated radiotherapy (20 Gy in 5 fractions) or a short course (8 Gy in 2 fractions) is indicated for metastatic spinal cord compression; a single 8 Gy dose is as effective as 20 Gy/5 fractions for pain control and neurological outcomes (Level 1 evidence) 19.
Systemic Treatment Options for Asymptomatic or Minimally Symptomatic Low‑Volume mCRPC
- For patients with little or no symptoms, the following agents have demonstrated radiographic progression‑free survival and overall‑survival benefits and should be offered: abiraterone + prednisone, enzalutamide, docetaxel, or sipuleucel‑T (Level 1 evidence) 15.
Clinical Pitfalls: Misuse of Local Radiotherapy
- Salvage radiotherapy that is appropriate for biochemical recurrence after prostatectomy in hormone‑sensitive disease should not be applied in the CRPC setting, because CRPC is a systemic disease and local prostate irradiation does not address metastatic progression (Level 1 evidence) 16, 17, 18.